A systematic review of outcomes of infants born to women receiving lopinavir/ritonavir (LPV/r) in pregnancy -- performed by investigators from the originator company -- suggests that in utero exposure may not increase the risk of preterm birth.
M Martinez presented data from an assessment of the vertical transmission rate and risk of adverse infant outcomes among women treated with LPV/r based regimens in pregnancy at the 4th HIV & Women Workshop, 2014.
The investigators searched PubMed/EMBASE databases and HIV conferences for studies published to the end of January 2013 or March 2013 respectively. They looked for randomised trials or prospective/retrospective cohort studies of outcomes of infants exposed to LPV/r in utero as a primary or secondary endpoint.
The investigators also searched the AbbVie Global Safety Database for the infant outcome of prematurity to the end of December 2011.
They included 27 publications (n=12) and abstract presentations (n=15) describing 17 studies in the review. These studies reported on 4331 women receiving LPV/r in pregnancy, of these 2263 received LPV/r 800/200 mg/day, 101 received >800/200 mg/day, and for 1967 the dose was undocumented. Table 1 shows the results.
|Table 1: Infant Outcomes From a Systematic Review of LPV/r in Pregnancy|
|Outcome||Studies Reporting Outcome (n)||Rate Reported (%)|
|Vertical transmission||10||0 - 2.8|
|Preterm birth||13||8.7 - 25.0|
|Very preterm birth||6||0.4 - 5.0|
|Low birth weight||6||0.4 - 5.0|
|Very low birth weight||4||0.3 - 3.0|
|Still birth||5||1.0 - 4.8|
|Infant mortality||4||0 - 5.8|
Post-marketing safety data from the company database showed a preterm rate of 0.66/10,000 patient treatment years for LPV/r.
One study showed similar preterm, low birth weight and vertical transmission rates for women receiving 800/200 mg and >800/200 mg LPV/r.
Three studies reporting birth defects showed a prevalence of 2% to 8.5%, which compared to the Antiretroviral Pregnancy Registry (APR) rate of 2.4%.
In one study the incidence of mortality among preterm infants was similar with LPV/r based treatment to that for women treated with triple NRTIs.
The authors concluded: "Preterm birth rates in the included studies reflected the rate for the geographical area in which the study was conducted; these data and post-marketing safety data suggest that in utero exposure to LPV/r may not increase risk of preterm birth. Infants born to women who received LPV/r 800/200 mg/day and those born to women who received >800/200 mg/day had similar rates of preterm birth, low birth weight, and MTCT."
Although analyses (particularly conclusions) performed by the originator company need to be approached with a little caution, these can be useful and results from this one supports the current APR data for LPV/r.
Martinez M et al. Systematic review of clinical outcomes of infants born to women receiving lopinavir/ritonavir-based antiretroviral therapy (ART) during pregnancy. 4th International Workshop on HIV & Women, Washington DC. 13-14 January 2014. Oral Abstract_21.
Links to other websites are current at date of posting but not maintained.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.